Compare ATYR & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATYR | ZBAI |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | 59 | 6 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 68.1M |
| IPO Year | N/A | N/A |
| Metric | ATYR | ZBAI |
|---|---|---|
| Price | $0.79 | $6.02 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.20 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 4.7K |
| Earning Date | 03-05-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $0.30 |
| 52 Week High | $7.29 | $11.94 |
| Indicator | ATYR | ZBAI |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 48.29 |
| Support Level | $0.67 | $5.40 |
| Resistance Level | $0.85 | $7.44 |
| Average True Range (ATR) | 0.05 | 0.52 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 8.89 | 70.28 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.